Clinical Trial Update: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1a/1b study of ACTM-838 in patients with advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ACTM-838

Snippet

Sponsor: Actym Therapeutics, Inc. | Conditions: Solid Tumor | Phase 1 | Status: TERMINATED